Last reviewed · How we verify

Cetirizine Dry Syrup

GlaxoSmithKline · Phase 3 active Small molecule

Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.

Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.

At a glance

Generic nameCetirizine Dry Syrup
SponsorGlaxoSmithKline
Drug classH1-receptor antagonist (second-generation antihistamine)
TargetH1-receptor
ModalitySmall molecule
Therapeutic areaAllergy/Immunology
PhasePhase 3

Mechanism of action

Cetirizine competitively binds to peripheral H1-receptors on mast cells and basophils, preventing histamine from triggering allergic cascade reactions. This reduces symptoms of allergies including itching, urticaria, and rhinitis. As a second-generation antihistamine, it has minimal central nervous system penetration due to its hydrophilic nature and low blood-brain barrier crossing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: